To help reduce the risk of subsequent stroke consider AGGRENOX for many of your TIA and ischemic stroke patients

Michael R.

  • Age: 60 years
  • Risk factors: History of prior TIA
  • ESPS 2
    ESPS 2 established the efficacy of AGGRENOX for reducing subsequent stroke risk in patients with prior ischemic stroke or TIA.1 See the safety and efficacy results

Robert F.

  • Age: 71 years
  • Risk factors: History of prior ischemic stroke and hypertension, and current smoker
  • ESPS 2: Included Patients With Multiple Risk Factors1 See the results

Susan M.

  • Age: 55 years
  • Risk factors: History of prior ischemic stroke
  • ESPS 2
    In ESPS2, AGGRENOX reduced the risk of subsequent stroke by 22.1% compared with aspirin (25mg BID).5 See the results

This flash element is not visible because you do not have Adobe® Flash Player 9. Click here to download the latest version free of charge. This link is provided to you as a convenience. Boehringer Ingelheim Pharmaceuticals, Inc. does not control, and is not responsible for, the content of any linked page.

Get Adobe Flash player

Treatment Guidelines

American Heart Association

The combination of aspirin and ER-DP is recommended (Class I,b Level of Evidence Bc )3 for the prevention of stroke in patients with TIA or stroke.

American College of Chest Physicians
National Stroke Association

Clinical Studies

ESPS 2 established the efficacy of AGGRENOX for reducing the risk of subsequent ischemic stroke.1 J Neurol Sci. 1996;143(1-2):1-13.

ESPS 2 included patients with multiple risk factors.1 J Neurol Sci. 1996;143(1-2):1-13.

The most common adverse events of AGGRENOX, including the incidence of headache, bleeding, and GI events in ESPS 2.1 J Neurol Sci.1996;143(1-2):1-13.

Review more clinical studies >

Patient Support

Life after an ischemic stroke can seem uncertain—your patients need strong support and resources to help them reduce their risk of subsequent stroke. Learn about a free patient support program >

A top priority in treating TIA or ischemic stroke patients is reducing their risk of subsequent stroke. Help your patients recognize the signs of a TIA >

a

Category 1: Based on evidence drawn from randomized controlled trials (RCTs), or meta-analyses based on RCTs, that have consistent results, narrow confidence intervals, and a low risk of bias.

b

Class I: There is evidence for and general agreement that treatment is useful and effective.

c

Level of Evidence B: Data derived from a single RCT or nonrandomized studies.

d

Grade 1A: Benefits clearly outweigh risk; supporting evidence is from RCTs without important limitations.

Important Safety Information

AGGRENOX is indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis.

AGGRENOX is contraindicated in patients with known allergy to nonsteroidal anti-inflammatory drugs (NSAIDs) and in patients with the syndrome of asthma, rhinitis, and nasal polyps.

In ESPS2, the risk of bleeding (including GI and intracranial hemorrhage) with AGGRENOX was comparable to aspirin and higher than placebo. Co-administration with anticoagulants or NSAIDs can increase the risk of bleeding. AGGRENOX should be avoided in patients with peptic ulcer disease or those having coagulation abnormalities due to liver disease or vitamin K deficiency. Patients who consume three or more alcoholic drinks daily should be counseled about the risk of increased bleeding.

AGGRENOX should be avoided during pregnancy due to the potential risk to the fetus. AGGRENOX should be avoided in patients with severe hepatic or renal insufficiency. Decreased renal function can occur with co-administration with NSAIDs.

The most frequently reported adverse event (AE) in ESPS2 was headache. Other frequently reported AEs (>10% and greater than placebo) were dyspepsia, abdominal pain, nausea, and diarrhea.

See the full AGGRENOX Prescribing Information.